PriceTargets.com logo

Quantum Biopharma - QNTM Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$10.00 As of 12/4/2025 05:00 PM ET
▲ +0.01 (0.10%)

This chart shows the closing price for QNTM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quantum Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QNTM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QNTM

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Quantum Biopharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $10.00.

This chart shows the closing price for QNTM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 polled investment analysts is to sell stock in Quantum Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/26/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/20/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
6/18/2025Singular ResearchUpgradeModerate Buy
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 9 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Quantum Biopharma logo
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $10.00
Low: $9.43
High: $10.08

50 Day Range

MA: $11.92
Low: $5.76
High: $18.45

52 Week Range

Now: $10.00
Low: $2.70
High: $38.25

Volume

64,650 shs

Average Volume

163,606 shs

Market Capitalization

$38.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Quantum Biopharma?

The following Wall Street sell-side analysts have issued stock ratings on Quantum Biopharma in the last twelve months: Singular Research, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for QNTM.

What is the current price target for Quantum Biopharma?

0 Wall Street analysts have set twelve-month price targets for Quantum Biopharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Quantum Biopharma in the next year.
View the latest price targets for QNTM.

What is the current consensus analyst rating for Quantum Biopharma?

Quantum Biopharma currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe QNTM will underperform the market and that investors should sell shares of Quantum Biopharma.
View the latest ratings for QNTM.

What other companies compete with Quantum Biopharma?

Other companies that are similar to Quantum Biopharma include Immix Biopharma, eXoZymes, Surrozen, Protalix BioTherapeutics and Compugen. Learn More about companies similar to Quantum Biopharma.

How do I contact Quantum Biopharma's investor relations team?

Quantum Biopharma's physical mailing address is 55 University Ave., Suite 1003, Toronto, ON M5J 2H7, Canada, . The company's listed phone number is 416-854-8884 and its investor relations email address is [email protected]. The official website for Quantum Biopharma is www.fsdpharma.com. Learn More about contacing Quantum Biopharma investor relations.